NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation (NASDAQ: RLYB), ...
In the version of this article initially published, the numbers in the 'R sym ' row in Table 1 are in the wrong columns. The error has been corrected in the HTML and ...
Zilucoplan is a subcutaneous, self-administered, macrocyclic peptide inhibitor of complement component 5. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ...
Credit: Shutterstock. Zilucoplan is a synthetic, macrocyclic peptide inhibitor of complement component 5. Positive topline results were announced from a phase 3 study evaluating the efficacy and ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume ...
WATERTOWN, Mass. and NEW HAVEN, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback